Search Medical Condition
Please enter condition
Please choose location

Hepatitis Clinical Trials

A listing of Hepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (493) clinical trials

Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

Fulminant and late-onset hepatic failure (LOHF) is intractable disease with high degree of fatality (70-80%). Only liver transplantation is established as a therapeutic modality to rescue patients with fulminant hepatic failure or LOHF. However, approximately 75% of the patients are not able to receive liver transplantation in Japan, and effective ...

Phase

Hepatic Hemodynamic Changes and Simulation in Living-Related Liver Transplantation

We use CT as tools to reconstruct 3D images of portal vein and hepatic artery before and one month after operation. The images are transferred to CAD and computer simulation is performed.

Phase N/A

Prevention of Decompensation in Liver Cirrhosis

Patients with cirrhosis tend to retain sodium and water leading to the development of ascites, which in the terminal stage of decompensation cannot be eliminated despite the use of massive diuretic treatment. These decompensated patients have a very high mortality of 50 % within 3 years and morbidity, and until ...

Phase

Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection

Peginterferon alfa-2 with ribavirin is the current standard of care for the treatment of HCV infection; however, severe hematologic effects, including anemia, leukopenia, and thrombocytopenia, may make this treatment less than ideal for patients with HCV. Medications to prevent or treat serious neutropenia and anemia have been established and are ...

Phase N/A

Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Study population: 30 patients will be included who meet all the following criteria: ALT > 2 times normal range; liver histology revealing NASH (type 2-4), without cirrhosis; clinical characteristics of the metabolic syndrome as defined by the NCEP, but no overt diabetes; negative work-up for other causes of liver diseases ...

Phase N/A

Nonalcoholic Fatty Liver Disease in Taiwanese Children

[Study Subjects] Obesity was defined as the BMI value > 95 percentile by different age- and gender groups according to the standards of the Department of Health in Taiwan. [Data Collection] The following data were obtained for each subject: age, gender, BMI, waist and hip circumference. BMI was calculated as ...

Phase N/A

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

Hepatic encephalopathy is a frequent and occasionally refractory complication of cirrhosis and is associated with impaired quality of life. Its severity may not correlate with other parameters of liver dysfunction. Although multiple pathogenic mechanisms for the condition have been proposed, most include the participation of bacterial toxins, especially ammonia, produced ...

Phase

Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT

The rational for using MBIT in the management of HCV in patients with persistently normal (and slightly elevated) ALT: - If MBIT is impaired, this indicates fibrosis >2: a trigger to begin treatment - This strategy will enable treating patients with relatively severe disease that was not detected by biopsy. ...

Phase